Skip to content
OpenCapital
Get started

TransMedics Group, Inc. TMDX EPS (Diluted)

EPS (Diluted) at other companies

LivaNova logo
LivaNovaLIVN
$0.40+107%
ICU Medical logo
ICU MedicalICUI
$1.20+290%
Edwards Lifesciences logo
Edwards LifesciencesEW
$0.66+8.2%
United Therapeutics logo
United TherapeuticsUTHR
$5.82-12.2%
OSI Systems logo
OSI SystemsOSIS
$2.33-2.9%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S4×+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%—

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s EPS (diluted)?
TransMedics Group, Inc. (TMDX) reported EPS (diluted) of $0.20 in Q1 2026.
How has TransMedics Group, Inc.'s EPS (diluted) changed year-over-year?
TransMedics Group, Inc.'s EPS (diluted) decreased by 71.4% year-over-year, from $0.70 to $0.20.
What is the long-term trend for TransMedics Group, Inc.'s EPS (diluted)?
Over 3 years (2021 to 2025), TransMedics Group, Inc.'s EPS (diluted) has grown at a 44.6% compound annual growth rate (CAGR), from -$1.61 to $4.87.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.